Stay updated on T-DXd in HER2 Expressing Tumors Clinical Trial
Sign up to get notified when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.

Latest updates to the T-DXd in HER2 Expressing Tumors Clinical Trial page
- Check2 days agoChange DetectedEnrollment updated to 477 participants across 89 locations; many site locations and contact details were removed.SummaryDifference5%

- Check10 days agoChange DetectedAdded Gūrgaon, India and Naples, Italy as study locations and included a new publication citation (Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x. Epub 2024 Sep 11.) with Revision: v3.5.0.SummaryDifference0.1%

- Check17 days agoChange DetectedThe recruitment location entry was updated from Gūrgaon, India, 122001 to Gurgaon, India, 122001.SummaryDifference0.0%

- Check24 days agoChange DetectedAdded study site Gūrgaon, India (122001) to the Locations list and updated the revision from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check31 days agoChange DetectedAdded Gurgaon, India, 122001 as a location and removed Gūrgaon, India, 122001 as a location.SummaryDifference0.0%

- Check45 days agoChange DetectedRevision tag updated from v3.4.1 to v3.4.2, a minor label change with no impact on page content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to T-DXd in HER2 Expressing Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.